Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE

NICE

22 May 2020 - Draft guidance published today by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.

The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. 

The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder